Literature DB >> 3841364

Population pharmacokinetics of racemic warfarin in adult patients.

D R Mungall, T M Ludden, J Marshall, D W Hawkins, R L Talbert, M H Crawford.   

Abstract

The population pharmacokinetics of racemic warfarin was evaluated using 613 measured warfarin plasma concentrations from 32 adult hospitalized patients and 131 adult outpatients. Warfarin concentrations were measured in duplicate using a high-performance liquid chromatographic procedure. The pharmacokinetic model used was a one-compartment open model with first-order absorption (absorption rate constant set equal to 47 day-1) and first-order elimination. The extent of availability was assumed to be one. A linear regression model was used to evaluate the influence of various demographic factors on warfarin oral clearance. Age appeared to be an important determinant of warfarin clearance in this adult population. There was about a 1%/year decrease in oral clearance over the age range of 20-70 years. Smoking appeared to result in a 10% increase in warfarin clearance, while coadministration of the inducers phenytoin or phenobarbital yielded about a 30% increase in clearance. This study has yielded a predictive model that, when combined with appropriate pharmacological response data, may be useful in the design and adjustment of warfarin regimens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841364     DOI: 10.1007/bf01065653

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  23 in total

1.  Age as a determinant of sensitivity to warfarin.

Authors:  A M Shepherd; D S Hewick; T A Moreland; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  Determinants of anticoagulant control in patients receiving warfarin.

Authors:  K O'Malley; I H Stevenson; C A Ward; A J Wood; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Smoking and warfarin dosage.

Authors:  A A Mitchell
Journal:  N Engl J Med       Date:  1972-11-30       Impact factor: 91.245

5.  Clinical implications of enzyme induction.

Authors:  A Breckenridge; M Orme
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation.

Authors:  J M Svec; R W Coleman; D R Mungall; T M Ludden
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

7.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

8.  The influence of age on the response to anticoagulants.

Authors:  S Husted; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

9.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

10.  Warfarin sodium: steady-state plasma levels and patient age.

Authors:  K Hotraphinyo; E J Triggs; B Maybloom; A Maclaine-Cross
Journal:  Clin Exp Pharmacol Physiol       Date:  1978 Mar-Apr       Impact factor: 2.557

View more
  28 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Authors:  Y Merlé; A Mallet; E Schmautz
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

3.  Hydralazine dose-response curve analysis.

Authors:  D A Graves; K T Muir; W Richards; B W Steiger; I Chang; B Patel
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

4.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

Review 5.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

6.  The influence of assay variability on pharmacokinetic parameter estimation.

Authors:  D A Graves; C S Locke; K T Muir; R P Miller
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

7.  Evaluation of population (NONMEM) pharmacokinetic parameter estimates.

Authors:  S Vozeh; P O Maitre; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

8.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

Review 9.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

10.  Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Luis Almeida; Amílcar Falcão; Manuel Vaz-da-Silva; Teresa Nunes; Ana-Teresa Santos; José-Francisco Rocha; Carla Neta; Tice Macedo; C Fontes-Ribeiro; P Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2008-08-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.